Mouse and human FcR effector functions

• Published in: Immunological reviews Vol. 268; no. 1; pp. 25 - 51
• Main Authors: Bruhns, Pierre, Jönsson, Friederike
• Format: Journal Article
• Language: English
• Published: England Blackwell Publishing Ltd 01.11.2015; Wiley
• Series: Fc receptors
• Subjects: Animals; Animals, Genetically Modified; antibody-mediated disease; antibody-mediated therapy; Fc receptor; FcγR; high-affinity receptor; Humans; Immunoglobulin G - immunology; Immunoglobulin G - metabolism; Immunology; Life Sciences; Mice; Mice, Knockout; mouse models; Mutation; Protein Binding; Receptors, Fc - chemistry; Receptors, Fc - genetics; Receptors, Fc - metabolism; Receptors, IgG - genetics; Receptors, IgG - metabolism; mouse models; antibody-mediated therapy; Fc receptor; FcγR; high-affinity receptor; antibody-mediated disease
• ISSN: 0105-2896; 1600-065X
• DOI: 10.1111/imr.12350

Summary Mouse and human FcRs have been a major focus of attention not only of the scientific community, through the cloning and characterization of novel receptors, and of the medical community, through the identification of polymorphisms and linkage to disease but also of the pharmaceutical community, through the identification of FcRs as targets for therapy or engineering of Fc domains for the generation of enhanced therapeutic antibodies. The availability of knockout mouse lines for every single mouse FcR, of multiple or cell‐specific—‘à la carte’—FcR knockouts and the increasing generation of hFcR transgenics enable powerful in vivo approaches for the study of mouse and human FcR biology. This review will present the landscape of the current FcR family, their effector functions and the in vivo models at hand to study them. These in vivo models were recently instrumental in re‐defining the properties and effector functions of FcRs that had been overlooked or discarded from previous analyses. A particular focus will be made on the (mis)concepts on the role of high‐affinity IgG receptors in vivo and on results from antibody engineering to enhance or abrogate antibody effector functions mediated by FcRs.